ライフサイエンスコーパス: fibromyalgia

1 onic low back pain, knee osteoarthritis, and fibromyalgia).

2 low back pain, systemic lupus erythematosus, fibromyalgia).

3 ases such as cancer, multiple sclerosis, and fibromyalgia.

4 cy and safety of gabapentin in patients with fibromyalgia.

5 and safety in treating pain associated with fibromyalgia.

6 tion on depressive symptoms in patients with fibromyalgia.

7 ated depressive symptoms among patients with fibromyalgia.

8 ible for the chronic diffuse pain typical of fibromyalgia.

9 t of pain and other symptoms associated with fibromyalgia.

10 t of any treatment plan for the patient with fibromyalgia.

11 would result in pain relief in patients with fibromyalgia.

12 f ailments from carbon monoxide poisoning to fibromyalgia.

13 low back pain to a high of 68% (n = 23) for fibromyalgia.

14 r than sham acupuncture at relieving pain in fibromyalgia.

15 gional pain syndrome, sickle cell anemia, or fibromyalgia.

16 the group that received acupuncture to treat fibromyalgia.

17 sed by functional MRI among 29 subjects with fibromyalgia.

18 itamin D deficiency is often misdiagnosed as fibromyalgia.

19 ith rheumatoid arthritis, osteoarthritis, or fibromyalgia.

20 here are distinct subgroups of patients with fibromyalgia.

21 ribute to the development of the syndrome of fibromyalgia.

22 r other scales were highest in patients with fibromyalgia.

23 syndrome, the irritable bowel syndrome, and fibromyalgia.

24 cial than either drug alone in patients with fibromyalgia.

25 one breast implant recipients who often have fibromyalgia.

26 irst stimulated at 0.25Hz was more common in fibromyalgia.

27 c fatigue syndrome is much less than that of fibromyalgia.

28 ain and tenderness suffered by patients with fibromyalgia.

29 identify potential causal risk variants for fibromyalgia.

30 ly studied sample of patients diagnosed with fibromyalgia.

31 age scan to identify susceptibility loci for fibromyalgia.

32 study suggests a strong genetic component of fibromyalgia.

33 ffers a therapeutic benefit in patients with fibromyalgia.

34 hysical and mental function in patients with fibromyalgia.

35 ry, and generalized pain conditions, such as fibromyalgia.

36 e inhibitors (duloxetine and milnacipran) in fibromyalgia.

37 tensity in patients with neuropathic pain or fibromyalgia?

38 was found in 24.2% of silent nociceptors in fibromyalgia, 22.7% in small-fiber neuropathy, and 3.7%

39 LBP (3.9 kg) (P = 0.03) or the patients with fibromyalgia (3.5 kg) (P = 0.006).

40 was detected in 31% of silent nociceptors in fibromyalgia, 34% in small-fiber neuropathy, and 2.2% in

41 e of 2.1 million for 1995), 5.0 million have fibromyalgia, 4-10 million have carpal tunnel syndrome,

42 162 with rheumatoid arthritis (RA), 114 with fibromyalgia, 63 with osteoarthritis, 34 with systemic l

43 y bowel disease, hepatic encephalopathy, and fibromyalgia and burn injury.

44 The common co-existence of fibromyalgia and chronic abdominal pain could be due to

45 ated hypotension has been documented in both fibromyalgia and chronic fatigue syndrome.

46 tor-1 axis have been also documented in both fibromyalgia and chronic fatigue syndrome.

47 s of 30 female patients meeting criteria for fibromyalgia and compared with recordings from 17 female

48 al activity that applies to individuals with fibromyalgia and fits a counseling model of health behav

49 ith rheumatoid arthritis, osteoarthritis, or fibromyalgia and Internet and e-mail access (n = 855) we

50 Tai chi may be a useful treatment for fibromyalgia and merits long-term study in larger study

51 Fibromyalgia and other "centralized" pain states are muc

52 occurred more frequently among patients with fibromyalgia and persons who regularly used CAM or used

53 was unrelated to treatment (exacerbation of fibromyalgia and rectal bleeding).

54 ded new insights into the pathophysiology of fibromyalgia and related chronic pain disorders.

55 tically exacerbates pain in diseases such as fibromyalgia and rheumatoid arthritis, but the underlyin

56 and functional benefits for individuals with fibromyalgia and should be included in treatment plans.

57 tions in other rheumatic conditions, such as fibromyalgia and systemic sclerosis.

58 etween chronic or widespread pain (including fibromyalgia) and mortality were included.

59 sive symptoms are common among patients with fibromyalgia, and behavioral intervention has been recom

60 is/CPPS, including irritable bowel syndrome, fibromyalgia, and chronic fatigue syndrome.

61 s with osteoarthritis, rheumatoid arthritis, fibromyalgia, and other musculoskeletal conditions.

62 e, neuropathy, headache or tension headache, fibromyalgia, and psychogenic pain) and subsequent suici

63 ciatica in adults less than 21 years of age, fibromyalgia, apophyseal and sacroiliac joint pain, and

64 In a subset of patients with fibromyalgia, approximately 50% of whom required narcoti

65 strated that chronic fatigue and symptoms of fibromyalgia are distributed as continuous variables in

66 While the basics of the treatment of fibromyalgia are included, the intent is to provide cont

67 n College of Rheumatology (ACR) criteria for fibromyalgia are the de facto criteria used for research

68 l activity and exercise for individuals with fibromyalgia are to improve or maintain general fitness,

69 n College of Rheumatology (ACR) criteria for fibromyalgia are used to identify individuals with both

70 sis and therapy is patients with symptoms of fibromyalgia (arthralgia, myalgia, fatigue) and oral and

71 widespread pain is several times higher than fibromyalgia as defined by the 1990 American College of

72 A wide spectrum of fibromyalgia-associated symptomatology and syndromes con

73 s occurring during the study were related to fibromyalgia-associated symptoms.

74 pelling evidence of a familial clustering of fibromyalgia cases in female sufferers; whether this clu

75 s similar to systemic pain syndromes such as fibromyalgia, chronic fatigue and irritable bowel syndro

76 agnosis of the patients with sicca symptoms, fibromyalgia, chronic fatigue, vague cognitive defects,

77 chronic musculoskeletal conditions, such as fibromyalgia, chronic low back pain and myofascial pain.

78 Patients with fibromyalgia commonly have symptoms of abdominal pain, s

79 In treating fibromyalgia, compared with placebo, pregabalin alone is

80 Basic research in fibromyalgia continues to pinpoint abnormal sensory proc

81 ducation and stretching for the treatment of fibromyalgia (defined by American College of Rheumatolog

82 nt among deployed than nondeployed veterans: fibromyalgia (deployed, 2.0%; nondeployed, 1.2%; odds ra

83 Because there is no gold standard for fibromyalgia diagnosis and because fibromyalgia is often

84 able to provide physician verification of a fibromyalgia diagnosis.

85 among patients who received acupuncture for fibromyalgia did not differ from that in the pooled sham

86 s, rheumatoid arthritis, osteoarthritis, and fibromyalgia differed significantly in their pain:ADL ra

87 heumatic disorder and pain syndromes such as fibromyalgia do not respond to traditional analgesic med

88 Fibromyalgia does not have a distinct cause or pathology

89 wel syndrome', 'Fibromyalgia', 'Dopamine and fibromyalgia', 'Dopamine and chronic fatigue syndrome' a

90 igue syndrome', 'Irritable bowel syndrome', 'Fibromyalgia', 'Dopamine and fibromyalgia', 'Dopamine an

91 tients with chronic pain, best classified as fibromyalgia, either primary or in association with othe

92 Accruing evidence shows that patients with fibromyalgia experience pain differently from the genera

93 al levels of pressure, patients with CLBP or fibromyalgia experienced significantly more pain and sho

94 e genotyped members of 116 families from the Fibromyalgia Family Study and performed a model-free gen

95 igation of these multicase families from the Fibromyalgia Family Study is warranted to identify poten

96 ven individuals meeting the ACR criteria for fibromyalgia finished the same battery of self-report an

97 Fibromyalgia (FM) and chronic fatigue syndrome (CFS) are

98 outcomes were compared between patients with fibromyalgia (FM) and controls.

99 ive-behavioral therapy (CBT) was superior to fibromyalgia (FM) education in reducing functional disab

100 Fibromyalgia (FM) is a chronic widespread pain condition

101 Fibromyalgia (FM) is considered to be the prototypical c

102 evelopment of novel treatment strategies for fibromyalgia (FM) is the lack of an objective marker tha

103 A subset of fibromyalgia (FM) patients have a dysfunctional hypothal

104 People with fibromyalgia (FM) report a number of physical, cognitive

105 Fibromyalgia (FM) represents a complex disorder that is

106 In evaluating the effectiveness of fibromyalgia (FM) therapies, it is important to assess t

107 t data derived from a study of patients with fibromyalgia (FM) to examine variability of pain over ti

108 The sensitivity for fibromyalgia (FM) was 0.48 (95% CI 0.28-0.68).

109 Fibromyalgia (FM), a common chronic pain condition chara

110 owing marked comorbidity with depression and fibromyalgia (FM), both of which are associated with dys

111 er (MDD) on pain processing in patients with fibromyalgia (FM).

112 physiology of chronic pain syndromes such as fibromyalgia (FM).

113 siology of functional pain syndromes such as fibromyalgia (FM).

114 nt review is intended to give an overview of fibromyalgia for the anesthesiologist.

115 imia nervosa, cataplexy, dysthymic disorder, fibromyalgia, generalized anxiety disorder, irritable bo

116 table recordings of 186 C nociceptors in the fibromyalgia group, 114 from small-fiber neuropathy pati

117 hyperalgesia in this group as well as in the fibromyalgia group; the pressure required to produce sli

118 pain-related cortical areas in the CLBP and fibromyalgia groups (in the contralateral primary and se

119 Familial aggregation of fibromyalgia has been increasingly recognized.

120 acy of these interventions for patients with fibromyalgia has not been established.

121 Fibromyalgia has received the most attention albeit most

122 ms (such as the irritable bowel syndrome and fibromyalgia) have been shown to have significantly high

123 outcome measures were the total score on the Fibromyalgia Impact Questionnaire (FIQ) and FIQ VAS scor

124 The primary end point was a change in the Fibromyalgia Impact Questionnaire (FIQ) score (ranging f

125 iaries) on a visual analog scale (PVAS), the Fibromyalgia Impact Questionnaire (FIQ) score, and the P

126 Co-primary outcome measures were the Fibromyalgia Impact Questionnaire (FIQ) total score (sco

127 omes were the weekly mean pain score and the Fibromyalgia Impact Questionnaire (FIQ) total score at w

128 ore changes in the Tender Points (TPs) test, Fibromyalgia Impact Questionnaire (FIQ), Health Assessme

129 measures included a tender point score, the Fibromyalgia Impact Questionnaire (FIQ), the Beck Depres

130 Secondary outcome measures were the Fibromyalgia Impact Questionnaire (FIQ), the Multidimens

131 Short Form 36 Health Survey (SF-36) and the Fibromyalgia Impact Questionnaire (FIQ).

132 (6-minute walk test), and functional status (Fibromyalgia Impact Questionnaire [FIQ]) before and afte

133 oms of fibromyalgia were evaluated using the Fibromyalgia Impact Questionnaire and the Short Form 36

134 severity score on the Brief Pain Inventory, Fibromyalgia Impact Questionnaire total score (all P < 0

135 the BPI average pain interference score, the Fibromyalgia Impact Questionnaire total score, the Clini

136 the Pittsburgh Sleep Quality Index, and the Fibromyalgia Impact Questionnaire.

137 ng the 206 patients, the clinician diagnosed fibromyalgia in 49.0%, while 29.1% satisfied ACR criteri

138 lf-report questionnaire for the diagnosis of fibromyalgia in lieu of the previously required tender p

139 atologists, and rheumatologists may diagnose fibromyalgia in patients who do not satisfy the ACR crit

140 ent for many of the symptoms associated with fibromyalgia in subjects with or without major depressiv

141 nerve fibers of the cornea of patients with fibromyalgia in terms of density, length and branching a

142 The prevalence of fibromyalgia in the general population was found to be 2

143 e most important pathophysiologic studies in fibromyalgia included evidence of altered blood flow to

144 Fibromyalgia is a common chronic pain condition for whic

145 Fibromyalgia is a common chronic pain disorder character

146 Primary fibromyalgia is a common yet poorly understood syndrome

147 Recent evidence suggests that fibromyalgia is a disorder characterized by dysfunctiona

148 Effective treatment for fibromyalgia is now possible.

149 ndard for fibromyalgia diagnosis and because fibromyalgia is often viewed as a trait diagnosis, all m

150 ic studies continue to provide evidence that fibromyalgia is part of a spectrum of chronic widespread

151 Fibromyalgia is present in as much as 2% to 8% of the po

152 Fibromyalgia may be considered as a discrete diagnosis o

153 hematosus, amyotrophic lateral sclerosis, or fibromyalgia might be related to Gulf War service.

154 n = 11, n = 19), arthralgia (n = 24, n = 7), fibromyalgia (n = 4, n = 11), and multiple symptoms with

155 LBP (n = 11), patients with widespread pain (fibromyalgia; n = 16), and healthy control subjects (n =

156 The impact of fibromyalgia on anesthesia care is not known.

157 ority status, higher education, diagnosis of fibromyalgia or osteoarthritis, and poorer health.

158 een sexual abuse and a lifetime diagnosis of fibromyalgia (OR, 1.61; 95% CI, 0.85-3.07, I(2) = 0%; 4

159 ved between rape and a lifetime diagnosis of fibromyalgia (OR, 3.35; 95% CI, 1.51-7.46), chronic pelv

160 gram that was specifically designed to treat fibromyalgia, or 1 of 3 sham acupuncture treatments: acu

161 ic disorders, e.g. irritable bowel syndrome, fibromyalgia, or migraine.

162 re enrolled in a 7-year prospective study of fibromyalgia outcome.

163 n central pain states) were shown to benefit fibromyalgia pain in an experimental setting.

164 Moderate-to-severe fibromyalgia pain significantly impairs HRQOL, and effec

165 nd study of patients with moderate-to-severe fibromyalgia pain.

166 rocessing as being integral to understanding fibromyalgia pain.

167 specific and clinically beneficial impact on fibromyalgia pain.

168 Thirty-one women with fibromyalgia participated in the randomized, double-blin

169 Fibromyalgia patients averaged almost 10 outpatient medi

170 edures were used to distinguish subgroups of fibromyalgia patients based on these domains.

171 The mechanosensitive nociceptors in the fibromyalgia patients behaved normally, but the silent n

172 ally, but the silent nociceptors in 76.6% of fibromyalgia patients exhibited abnormalities.

173 Five hundred thirty-eight fibromyalgia patients from 6 rheumatology centers were e

174 Cognitive dysfunction in fibromyalgia patients has been reported, especially when

175 show for the first time that the majority of fibromyalgia patients have abnormal C nociceptors.

176 Fibromyalgia patients have high lifetime and current rat

177 Research continues to demonstrate that fibromyalgia patients have neurophysiologic abnormalitie

178 a and/or windup), yielded four phenotypes of fibromyalgia patients in a subgroup analysis: one group

179 ge yearly cost for service utilization among fibromyalgia patients is $2,274.

180 fore, it seems useful to identify subsets of fibromyalgia patients on the basis of which of these fac

181 There appears to be a group of fibromyalgia patients who exhibit extreme tenderness but

182 The distinction between fibromyalgia patients with low titer antinuclear antibod

183 ing of conduction velocity is more common in fibromyalgia patients, and may constitute a distinguishi

184 e comorbid mood disorders are more common in fibromyalgia patients, studies have shown that fibromyal

185 ivity is associated with spontaneous pain in fibromyalgia patients.

186 nal cord lesions, but also disorders such as fibromyalgia, phantom limb pain and tension-type headach

187 In conclusion, half of the tested fibromyalgia population demonstrates signs of small fibe

188 ender point examination, survey criteria for fibromyalgia (Regional Pain Scale score > or =8 and fati

189 th study period, patients used a mean of 2.7 fibromyalgia-related drugs.

190 Participants with fibromyalgia reported more ill health on condition-speci

191 100% of Israeli patients with posttraumatic fibromyalgia returned to work.

192 Participants (n = 619) with fibromyalgia, rheumatoid arthritis, or osteoarthritis re

193 ghtly at risk of postwar hospitalization for fibromyalgia (RR = 1.23, 95% Cl: 1.05, 1.43); however, t

194 Patients with fibromyalgia scored lower than the US norm on all SF-36

195 Patients with established fibromyalgia, seen in rheumatology centers in which ther

196 efficacy of acupuncture in the treatment of fibromyalgia showed conflicting results, but added to th

197 Duloxetine treatment improved fibromyalgia symptoms and pain severity regardless of ba

198 ionnaires which included questions regarding fibromyalgia symptoms and severity, utilization of servi

199 bromyalgia patients, studies have shown that fibromyalgia symptoms are not explained by depression al

200 All patients had persistence of some fibromyalgia symptoms, although almost half (48%) had no

201 n findings have previously been described in fibromyalgia syndrome (FMS) by single-photon-emission co

202 Juvenile fibromyalgia syndrome (FMS) is a chronic musculoskeletal

203 Fibromyalgia Syndrome (FMS) is a chronic pain condition

204 Fibromyalgia Syndrome (FMS) is a frequent comorbidity in

205 Fibromyalgia syndrome (FMS) is characterized by uncertai

206 Fibromyalgia syndrome (FMS) is characterized by widespre

207 The optimal management of fibromyalgia syndrome (FMS) is unclear and comprehensive

208 ditures differ between insured patients with fibromyalgia syndrome (FMS) who visit complementary and

209 g and poor medical outcomes in patients with fibromyalgia syndrome (FMS), neither assessed these find

210 iate, pain onset and health care seeking for fibromyalgia syndrome (FMS).

211 those of Irritable Bowel Syndrome (IBS) and Fibromyalgia Syndrome (FMS).

212 line and 1-year followup among patients with fibromyalgia syndrome (FMS).

213 onships of adolescents with juvenile primary fibromyalgia syndrome (JPFS) compared with matched class

214 ability of adolescents with juvenile primary fibromyalgia syndrome (JPFS) to cope with their conditio

215 A model of fibromyalgia syndrome produced by chronic unpredictable

216 g postoperative pain, noncardiac chest pain, fibromyalgia syndrome, and chronic back pain.

217 ypothesis that tender points, as part of the fibromyalgia syndrome, are strongly associated with spec

218 idespread pain, the clinical hallmark of the fibromyalgia syndrome, is associated with other physical

219 nkylosing spondylitis, rheumatoid arthritis, fibromyalgia) than those with NWU or LWU.

220 merous treatments are available for managing fibromyalgia that are supported by high-quality evidence

221 s for the treatment of pain in patients with fibromyalgia that may be also useful in patients with ot

222 Primary outcome measures included fibromyalgia, the chronic fatigue syndrome, dermatologic

223 ent is associated with an increased risk for fibromyalgia, the chronic fatigue syndrome, skin conditi

224 examined were the chronic fatigue syndrome, fibromyalgia, the irritable bowel syndrome, multiple che

225 igins of cerebral gray matter alterations in fibromyalgia, this study advances the understanding of t

226 l evidence of a beneficial effect of tDCS in fibromyalgia, thus encouraging further trials.

227 We found decreased gray matter in fibromyalgia to be associated with T1 relaxation times,

228 th professionals to counsel individuals with fibromyalgia to become and remain more physically active

229 asic exercise principles to individuals with fibromyalgia to encourage clinicians to discuss with the

230 n a recently developed putative rat model of fibromyalgia to innocuous and acute nociceptive stimuli

231 report of genome-wide suggestive linkage of fibromyalgia to the chromosome 17p11.2-q11.2 region.

232 sibling recurrence risk ratio (lambdas ) for fibromyalgia was 13.6 (95% confidence interval 10.0-18.5

233 lvic pain or prostatitis was 11% (8-17); and fibromyalgia was 4% (3-7).

234 Fibromyalgia was diagnosed in 46.8% of CLD patients.

235 The medical literature on fibromyalgia was reviewed from 1955 to March 2014 via ME

236 ble bowel syndrome, chronic pelvic pain, and fibromyalgia were assessed by questionnaires.

237 Patients with fibromyalgia were divided into tertiles by change in pai

238 College of Rheumatology criteria for primary fibromyalgia were enrolled (89% female, 87% white, mean

239 Other symptoms of fibromyalgia were evaluated using the Fibromyalgia Impac

240 s with other rheumatic disorders, those with fibromyalgia were more likely to have lifetime surgical

241 led trials of cyclobenzaprine in people with fibromyalgia were obtained from Medline, EMBase, Psyclit

242 oup, escalating-dose trial, 60 patients with fibromyalgia were randomized 2:1 (pramipexole:placebo) t

243 Forty females with fibromyalgia were randomized to receive active or sham t

244 merican College of Rheumatology criteria for fibromyalgia were randomized to receive esreboxetine at

245 Patients diagnosed with fibromyalgia were recruited from a Southern California h

246 steoarthritis (OA), rheumatoid arthritis, or fibromyalgia who were participating in a long-term outco

247 was performed to assess 1,025 patients with fibromyalgia who were randomized to receive milnacipran

248 tion on depressive symptoms in 91 women with fibromyalgia who were randomly assigned to treatment (n

249 ging to compare 26 postmenopausal women with fibromyalgia with 25 healthy controls (age range: 50-75

250 a model-free genome-wide linkage analysis of fibromyalgia with 341 microsatellite markers, using the

251 mmonly reported but anecdotal association of fibromyalgia with whiplash-type neck trauma was validate